Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Diamond

Showing results (281-290 of 344) with videos related to

Pageof 35
Sort By:
Diabetologia|June 16, 2000
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjectsD M Flavell, I Pineda Torra, Y Jamshidi, et al.
JAMA Oncology|October 23, 2018
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical TrialSylvia Adams, Jennifer R Diamond, Erika Hamilton, et al.
Investigational New Drugs|April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumorsJennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Cancer Medicine|October 16, 2020
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer CenterJennifer A Weiss, Andrew Nicklawsky, Jodi A Kagihara, et al.
Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
The New England Journal of Medicine|February 13, 1992
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative StudyJ D Hamilton, P M Hartigan, M S Simberkoff, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
Pageof 35

Showing results (281-290 of 344) with videos related to

Sort By:
Pageof 35
Diabetologia|June 16, 2000
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjectsD M Flavell, I Pineda Torra, Y Jamshidi, et al.
JAMA Oncology|October 23, 2018
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical TrialSylvia Adams, Jennifer R Diamond, Erika Hamilton, et al.
Investigational New Drugs|April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumorsJennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Cancer Medicine|October 16, 2020
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer CenterJennifer A Weiss, Andrew Nicklawsky, Jodi A Kagihara, et al.
Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
The New England Journal of Medicine|February 13, 1992
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative StudyJ D Hamilton, P M Hartigan, M S Simberkoff, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
Pageof 35